William T. Miller

Vaxcyte is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the threat of bacterial diseases. The company utilizes its proprietary cell-free protein synthesis platform, XpressCF, which was licensed from Sutro Biopharma, to design and produce complex conjugate vaccines. Vaxcyte's lead candidate, VAX-31, is a 31-valent pneumococcal conjugate vaccine (PCV) currently in Phase 3 development, designed to provide broader protection than existing standards of care. The company's pipeline also includes candidates for periodontitis and shigellosis, leveraging its ability to precisely attach polysaccharides to carrier proteins.